WAICF
The World AI Cannes Festival will take place in Cannes on February 9, 10 and 11 2023. This is the top world event dedicated exclusively to AI, tech leaders innovating in AI and the economic, human and societal issues that will impact our lives in the short term.
The event is a chance to get up to speed on the current marketplace, learn from the best experts and to meet decision-makers and top business leaders. Many notable speakers will deliver presentations and lead strategic conferences, think-tank workshops, exhibition stands and networking sessions.
Spotlight on the major speakers for 2023
The WAICF is an opportunity for artificial intelligence professionals and experts , whether from professional backgrounds, research or public administrations, to meet and exchange views on developments in the sector.
The 100+ international speakers at the WAICF in 2023 will include:
- Yann Lecun, Vice-President and Chief AI Scientist, Meta AI
- Joann Stonier, Chief Data Officer, Mastercard
- Wolfgang Hauner, Head of Group Data Analytics, Allianz
- Saeed Contractor, Global Head of Intelligent Automation COE, Uber
- Manuela M. Veloso, Head, J. P. Morgan Chase AI Research
- Xavier Lagardere, Chief Data Officer, Vice President Data Strategy and Transformation, Lufthansa Group
- Stuart Russell, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, University of California, Berkeley
- Alberto Prado, Vice-President, Global Head of R&D Digital & Partnerships, Unilever
- Divya Dwivedi, Advocate, Supreme Court of India
- Aidan Gomez, Co-Founder and CEO, Cohere
- Thomas Wolf, Co-Founder and Chief Science Officer, Hugging Face
- John Kamara, Founder and CEO/founder, Adanian Labs/AI Center of Excellence (AICE)
- Michael Kearns, Amazon Scholar, University of Pennsylvania
- Michaela Schutt, SVP, Head of Global Talent Acquisition Ecosystem, Siemens
- Nozha Boujemaa, Global VP - Digital Ethics and Responsible AI, IKEA Retail
- Oren Etzioni, CEO, Allen Institute for AI
The Festival will provide an overview of AI in all its diversity through 5 key conference tracks:
- AI FOR SOCIETY: Understand the benefits of AI for society and our planet, and the challenges that must be met.
- AI TODAY AND TOMORROW: Explore what AI can do today, and picture what future innovations will offer tomorrow's society and organizations.
- AI STRATEGY: Get key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: Learn how best to use the different AI technologies, and shape your innovation mindset with top-level speakers.
- AI APPLICATIONS: Get an overview of the advances organizations can make using AI, through focuses on various industries.
Full list of conferences and speakers
Get accreditation through the media pass site
About World AI Cannes Festival
The World AI Cannes Festival brings together industry experts, professionals, and the general public to attend exhibitions, workshops, happenings, conferences, networking and meet-ups with an international dimension. The rich and varied program highlights the latest AI applications in business and in everyday life. A unique opportunity for national and international institutions, associations, businesses and start-ups across the world to meet their target audiences, highlight their expertise and demonstrate their commitment to ethical and sustainable AI.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005541/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom